Setmelanotide is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Phase 3 TRANSCEND trial: -18.4% placebo-adjusted BMI reduction at 52 weeks. FDA approved November 2020 for genetic obesity (POMC/PCSK1/LEPR deficiency). March 2026 expanded for acquired hypothalamic obesity. Setmelanotide is fda-approved (imcivree) for genetic and acquired hypothalamic obesity. prescription medication.
What Does the Research Say About Setmelanotide?
Phase 3 TRANSCEND trial: -18.4% placebo-adjusted BMI reduction at 52 weeks. FDA approved November 2020 for genetic obesity (POMC/PCSK1/LEPR deficiency). March 2026 expanded for acquired hypothalamic obesity.
Setmelanotide (Setmelanotide (MC4R agonist)) is a Melanocortin-4 receptor agonist. Research interest has focused on its potential effects on weight loss in genetic obesity, appetite reduction, energy expenditure increase, BMI reduction.
What Is the Evidence for Setmelanotide's Mechanism?
Directly activates melanocortin-4 receptors (MC4R) in the hypothalamic paraventricular nucleus, bypassing upstream leptin-POMC pathway defects. MC4R activation suppresses hunger signaling through AgRP neurons while activating POMC neurons, resulting in sustained satiety and increased energy expenditure independent of leptin pathway integrity.
These pathways have been identified through in vitro studies, animal models, and where available, human trials.
Are There Human Clinical Trials for Setmelanotide?
Phase 3 TRANSCEND trial: -18.4% placebo-adjusted BMI reduction at 52 weeks. FDA approved November 2020 for genetic obesity (POMC/PCSK1/LEPR deficiency). March 2026 expanded for acquired hypothalamic obesity.
The gap between preclinical promise and clinical validation remains the biggest challenge in peptide research. However, Setmelanotide has shown preliminary results.
What Does the Safety Research Show?
Hyperpigmentation (skin, moles, lips) most common — reversible upon discontinuation. Injection site reactions, nausea, headache. Generally well-tolerated.
Setmelanotide is fda-approved (imcivree) for genetic and acquired hypothalamic obesity. prescription medication.
What Makes Setmelanotide Unique in Research?
The only FDA-approved treatment specifically targeting genetic forms of obesity via MC4R agonism — addresses the root cause of hypothalamic obesity rather than symptomatic appetite suppression.
This differentiator is important because it means Setmelanotide fills a role that other compounds in its class may not fully replicate.
Bottom Line on Setmelanotide Research
The evidence base for Setmelanotide is growing. Key research areas include weight loss in genetic obesity, appetite reduction, energy expenditure increase, BMI reduction.
Stay current with PubMed searches for Setmelanotide for the latest publications.
Complete Guide
Setmelanotide : Benefits, Dosage, Side Effects & Research
Related Reading
- Setmelanotide Dosage Guide
- Setmelanotide Benefits
- Setmelanotide Side Effects
- Setmelanotide Stacking Guide
- Setmelanotide Cycle Guide
- ARA-290 Complete Guide
Calculate Your Setmelanotide Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for Setmelanotide.
Open Calculator →Research-Grade Sourcing
If you're going to research Setmelanotide, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is Setmelanotide?
Setmelanotide (Setmelanotide (MC4R agonist)) is a Melanocortin-4 receptor agonist. Developed by Rhythm Pharmaceuticals as first-in-class MC4R agonist for genetic obesity. It is researched for weight loss in genetic obesity, appetite reduction, energy expenditure increase, BMI reduction.
What is the recommended Setmelanotide dosage?
Common dosages: 1-3 mg daily administered once daily via subcutaneous injection. Cycle length: ongoing continuous therapy. Half-life: not publicly disclosed. Use our peptide calculator for exact reconstitution math.
What are the side effects of Setmelanotide?
Hyperpigmentation (skin, moles, lips) most common — reversible upon discontinuation. Injection site reactions, nausea, headache. Generally well-tolerated.
Is Setmelanotide safe?
Setmelanotide has shown a favorable safety profile in research. FDA-approved (Imcivree) for genetic and acquired hypothalamic obesity. Prescription medication. All research should follow appropriate safety protocols.